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Abstract 
Background: To determine the effect of combined 
supplementation of pioglitazone and levo carnitine 
on plasma glucose, insulin resistance and serum 
adiponectin in T2DM mice.    
Methods: In this randomized controlled trial 40 
healthy BALB/c mice were divided into four groups 
(n=10 each). Mice were fed high fat diet for two 
weeks followed by intraperitoneal injection of 
streptozotocin to induce T2DM. Group I served as 
diabetic control. Group II was administered 
pioglitazone. Group III  received levo carnitine and 
group IV was supplemented combined pioglitazone 
and levo carnitine. After six days of 
supplementation, terminal intra-cardiac blood 
extraction was carried out and samples were 
analyzed for plasma glucose, insulin resistance and 
serum adiponectin levels.  
Results: Plasma glucose levels and insulin 
resistance significantly decreased in the combined 
supplementation group compared to the diabetic 
control. Serum adiponectin levels showed 
significant increase in combined supplemented 
group when compared with diabetic control and levo 
carnitine groups. The data also revealed a positive 
correlation between plasma glucose and insulin 
resistance and a negative correlation of these two 
parameters with serum adiponectin levels.  
Conclusions: The combined supplementation of 
pioglitazone and levo carnitine significantly 
improved glycemic control, insulin resistance and 
serum adiponectin vis-à-vis individual 
supplementation in type 2 diabetic mice.  
Key Words:Insulin resistance, Adiponectin, 
Pioglitazone, Levo carnitine, Type2 diabetes mellitus 
 
Introduction 
          Type 2 diabetes mellitus is a complex 
heterogeneous group of metabolic disorders including 
hyperglycemia and impaired insulin action and/or 
insulin secretion. It causes dysfunction of multiple 
organs or tissues.1 Current theories of T2DM include a 
defect in insulin-mediated glucose uptake in muscles, 
dysfunction of the pancreatic beta-cells, disruption in 
secretory function of adipocytes, and impaired insulin 
action in liver. The etiology of human T2DM is 
multifactorial, with genetic background and physical 
inactivity as its two critical components.1 Obesity and 
weight gain are core contributors of T2DM and insulin 
resistance. T2DM is known to be associated with a 
range of many pathophysiological sequelae including 
hypertension, hyperlipidemia, atherosclerosis,etc.2 
Increased insulin resistance occurs early in the natural 
history of T2DM but is compensated by increased 
secretion of insulin by β cells of pancreatic islets. When 
β cell failure arises, the hyperinsulinemia no longer 
can compensate for the insulin resistance and glucose 
homeostasis deteriorates.3  
   Adipose tissue is now recognized as an important 
endocrine organ that secretes a number of biologically 
active proteins called “adipocytokines”. Adiponectin, 
is a novel adipocyte derived hormone also known as 
Acrp-30, Adipo-Q, apM-1 and GBP-284, which plays 
an important role in glucose metabolism and insulin 
resistance.5 Adiponectin gene is exclusively present 
abundantly in white adipose tissue and is a 244 amino 
acid, 30-KDa secreted protein with high structural 
homology to collagen VIII, X and complement C1q.5 In 
plasma, adiponectin circulates in high concentration, 
normally in the range of 3-30 µg/ml.6 Adiponectin 
exerts its effects through three cell membrane 
receptors, AdipoR-1, AdipoR-2 and T-cadherin.7 
Obesity is inversely related to adiponectin making 
adiponectin a negative marker of metabolic syndrome. 
It is now well established that adiponectin plays an 
important role in T2DM, hypertension and 
dyslipidemias but the most significant role of 
adiponectin is its insulin sensitizing effect. In diabetic 
patients, the levels of adiponectin in blood are lower 
than normal, while higher levels of adiponectin 
minimizes the risk of developing T2DM.8 In liver and 
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skeletal muscle, adiponectin improves glucose 
utilization and stimulates fatty acid oxidation through 
a pathway that involves activation of AMP Kinase 
(AMPK) and acetyl-CoA carboxylase (ACC).9 
     Pioglitazone is an oral antihyperglycemic agent 
belonging to a class thiazolidinediones (TZDs) and is 
widely used in the treatment of T2DM. Pioglitazone 
regulates glucose and lipid metabolism by activating 
the nuclear peroxisomes proliferator activated receptor 
gamma (PPAR-γ) which leads to increased 
transcription of different proteins thereby amplifying 
the post receptor action of insulin in the liver and 
peripheral tissues thus improving the glycemic 
control.10 Pioglitazone inhibits gluconeogenesis and 
increases the peripheral and splanchnic glucose 
uptake, thus augmenting the hepatic and peripheral 
insulin sensitivity.11 TZDs increases plasma 
adiponectin levels in animal models of obesity and 
diabetes, non-diabetic subjects and patients with 
T2DM. Thus it has been speculated that pioglitazone 
increases insulin sensitivity by mediating the 
hypoadiponectinemia in type2 diabetes. 12  
     Levo-carnitine is a quaternary ammonium 
compound that appears as a white crystalline, 
hygroscopic powder. Levo carnitine (β-hydroxy-γ-
trimethylaminobutyrate) is a natural vitamin which is 
abundantly present in mammalian plasma and tissues. 
It is mainly distributed in skeletal and cardiac muscles. 
It is supplied to the body through dietary sources like 
meat and dairy products. It is also biosynthesized 
from lysine and methionine in the body. Its main 
function is to transport long-chain fatty acids across 
the inner mitochondrial membrane into the matrix for 
β-oxidation.13 Levo carnitine infusion significantly 
improves insulin sensitivity and stimulates glucose 
uptake by skeletal muscles in healthy subjects and 
type 2 diabetic patients. Stimulation of glucose 
oxidation is manifested only in type 2 diabetic 
patients. There is a significant decrease in the plasma 
lactate levels after levo carnitine administration as 
well. These observations suggest levo carnitine-
induced activation of the pyruvate dehydrogenase 
complex.14 Levo carnitine acts as an antioxidant, it is 
an intracellular superoxide scavenger that improves 
mitochondrial functions and reduces DNA damage.   
Acetyl-levo carnitine infusion acutely enhances insulin 
sensitivity in type 2 diabetics with insulin resistance.15  
     The probable function of pioglitazone and levo 
carnitine in T2DM have been explored independently. 
However no interrelationship has so far been 
documented. Keeping this in view, the present study 
has been designed to evaluate the effects of combined 
supplementation of pioglitazone and levo carnitine on 
plasma glucose, insulin resistance and serum 
adiponectin in T2DM. 
 
Material and Methods 
   This study was undertaken at Department of 
Physiology, Army Medical College, Rawalpindi, in 
collaboration with National Institute of Health (NIH), 
Islamabad. Blood glucose was measured by GOD-POD 
method. Enzyme linked immunosorbent assay (ELISA) 
was used to measure serum adiponectin. Serum 
triglycerides and serum HDL-C were estimated 
spectrophotmetrically.  
     The study was conducted on 8-12 weeks old, 40 
healthy BALB/c mice purchased from National 
Institute of Health, Islamabad. Average weight of 
mouse was 28.07 ± 0.1 g. Mice were divided into four 
equal groups. Free access to food and water was 
provided and the room was well ventilated with 
controlled temperature range of 20-22°C. 12 hours light 
and dark cycles were maintained. 
    Mice in all the four groups were fed on high fat diet 
ad libitum for 2 weeks after which 4 intra-peritoneal 
injections of streptozocin were given in the dose of 
40mg/kg for 4 consecutive days.16 The mice continued 
to be fed on high fat diet during the 3rd week and no 
other supplementation was given during that period. 
At the end of the 4th week (after 10 days of STZ 
administration), mice were checked to confirm the 
development of T2DM by measuring the fasting 
plasma glucose (mg/dl). The blood glucose level > 252 
mg/dl (14mmol/l) was taken as the cut off value for 
confirming diabetes mellitus.17 After establishing type 
2 diabetes mellitus in all four groups, at the conclusion 
of 4th week, diabetic control group was supplemented 
with normal saline, pioglitazone  group with 
pioglitazone (10 mg/kg body weight)18, levo carnitine 
group with levo carnitine (200 mg/kg body weight)19 
and combined group with combined supplementation 
of pioglitazone and levo carnitine for 6 days. The 
terminal sample (1.5-2ml blood) was drawn at the end 
of the 5th week by a single intra cardiac puncture after 
12 hours overnight fast.Data within the groups were 
analyzed by using ANOVA (one way analysis of 
variance) followed by Tukey’s HSD. p < 0.05 was 
considered statistically significant.  
Results 
    The average weight of the mice was 28.07±0.10 
grams at the start of the experiment. At the end of the 
4th week of experiment (prior to the drug 
supplementation), the weight of mice in all the four  
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groups was found increased but had no statistical 
difference (p>0.05) amongst the groups (Table 
1).Profound hyperglycaemia was developed in all the 
four groups having insignificant difference (p>0.05) 
amongst the groups (Table 1). Fasting plasma glucose 
of mice at the end of 5th week (after drug 
supplementation) showed a significant difference 
(p<0.001) amongst all the groups (Table 2). The 
combined supplementation revealed a highly 
significant reduction (p<0.001) in glycemic profile 
compared to the diabetic control (Table 3). Individual 
supplementation with pioglitazone and levo carnitine 
showed significant effect (p<0.001) when compared to 
the diabetic control. The glycemic control exerted by 
the combined supplementation of both the drugs was 
significantly pronounced (p<0.05) when compared 
with the levo carnitine group but not significant 
(p>0.05) when compared with pioglitazone group 
(Table 3).  
Table-1:Plasma glucose and body weight 
between diabetic control, pioglitazone, levo 
carnitine, and combined supplementation 
groups by ANOVA 
 Diabetic 
control 
Pioglitazone Levo-
carnitine 
Combined p-
value 
Plasma 
glucose 
(mg/dl) 
379.6 ± 
39.66 
386.2 ± 45.15 404.8 ± 43.15 390.4 ± 39.34 >0.05 
Body weight 
(gm) 
33.12 ± 
2.40 
35.07 ± 1.32 36.40 ± 2.12 35.62 ± 2.65 >0.05 
Values are expressed as mean + SD 
 
   Insulin resistance (IR) was measured by TG/HDL 
ratio (which is a surrogate marker for assessing IR and 
its cut off value was ≥ 1.80).20 After the drug 
supplementation the IR showed significant difference 
(p<0.001) amongst all the four groups (Table 2). IR was 
higher than cut off value in the diabetic control group 
and decreased values were seen in pioglitazone, levo 
carnitine and combined groups (Table 2). The 
combined supplementation group showed significant 
reduction in IR (p<0.001) when compared to the 
diabetic control group. Individual supplementation of 
pioglitazone and levo carnitine also exhibited 
significant reduction in IR (p <0.001) when compared 
to the diabetic control group. The IR revealed 
reduction in combined supplementation group but 
difference was not significant (p>0.05) when compared 
to the pioglitazone and levo carnitine groups (Table 
3).The data showed significant difference (p<0.001) in 
serum adiponectin levels amongst the groups after the 
drug supplementation. Its level was reduced in 
diabetic control group and significantly increased 
(p<0.001) in drug supplemented groups (Table 2).  
Table-2:Plasma glucose, insulin resistance (IR) 
and serum adiponectin levels amongst the 
diabetic control, pioglitazone, levo carnitine and 
combined supplementation groups by ANOVA 
Parameters Diabetic 
control 
Pioglitazone Levo-
carnitine 
Combined p-
Value 
Plasma glucose 
(mg/dl) 
413.70 + 
39.45 
252.50 + 
48.00 
300.50 + 
33.54 
238.70 + 42.02 < 0.001 
Insulin 
resistance  
TG: HDL ratio 
3.23 + 
0.95 
1.48 + 0.46 1.824 + 
0.60 
1.25 + 0.20 < 0.001 
Serum 
adiponectin 
(ng/dl) 
3.97 + 
0.078 
7.81 + 1.65 4.42 + 
0.87 
8.35 + 1.65 < 0.001 
Value are expressed as mean + SD 
Table 3:Plasma glucose, insulin resistance and 
serum adiponectin amongst the four groups 
after drug supplementation by post-Hoc 
Tukey’s test. 
Group Comparison Plasma 
glucose 
Insulin 
resistance 
Serum 
adiponectin 
Pioglitazone vs. diabetic 
control 
< 0.001 < 0.001  < 0.001 
Levo-carnitine vs. diabetic 
control 
< 0.001 < 0.001 0.948 
Pioglitazone vs. levo 
carnitine 
0.060 0.621 0.001 
Combined vs. diabetic 
control 
< 0.001 < 0.001  < 0.001 
Combined vs. pioglitazone 0.0876 0.189 0.917 
Combined vs. levo 
carnitine 
0.010 0.837 < 0.001 
 
Table -4:Pearson correlation between plasma 
glucose, insulin resistance and serum 
adiponectin levels 
Parameters r-value p-value 
Plasma glucose 
(mg/dl) vs. 
Insulin resistance (IR) r = 0.48 p = 0.002 
Serum adiponectin (ng/dl) r = -0.47 p = 0.002 
Insulin 
resistance (IR) 
vs. 
Plasma glucose (mg/dl) r = 0.48 p = 0.002 
Serum adiponectin r = -0.33 p = 0.03 
  The serum adiponectin level significantly increased 
(p<0.001) in combined supplementation group when 
compared to the diabetic control group. Whereas 
pioglitazone group presented significant increase 
(p<0.001) in serum adiponectin level when compared 
to the diabetic control group and levo carnitine 
showed no significant increase (p>0.05) when 
compared to diabetic control group. When compared 
the individual effects, the difference was not 
significant (p>0.05) between combined and 
pioglitazone groups but significant (p<0.001) in 
increasing the serum adiponectin levels as compared 
to the levo carnitine group (Table 3). The Pearson’s 
correlation coefficient between plasma glucose, insulin 
resistance and serum adiponectin revealed that plasma 
glucose was positively correlated with insulin 
resistance and negatively correlated with serum 
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adiponectin. Whereas correlation between insulin 
resistance and serum adiponectin was negative, that 
manifested the insulin resistance in either groups and 
greater reduction in adiponectin level (Table 4). 
 
Discussion 
The mouse model of T2DM was prepared by high fat 
diet and intraperitoneal injection of streptozotocin 
(STZ) in the dose of 40 mg/kg body weight for 4 days 
because it closely resembled the gradual progression 
from obesity to insulin resistance and T2DM, which 
were the hallmarks of human phenotype.17 
Confirmation of T2DM was done checking fasting 
blood glucose levels. The blood glucose level more 
than 252 mg/dl was taken as the cut off value for 
confirming T2DM.18  
     After the confirmation of the T2DM and prior to the 
drug supplementation, the glucose levels in all the 
groups ranged between 379-404 mg/dl. Pioglitazone 
supplementation resulted in statistically significant 
decrease in plasma glucose levels in pioglitazone 
group (252.50 + 48.00 mg/dl) when compared with 
diabetic control group (413.70 + 39.45 mg/dl). It is well 
documented that thiazolidinedione (TZD) such as 
pioglitazone decreases blood glucose in diabetic 
animal models and patients with T2DM. Pioglitazone 
being a PPAR-γ agonist increases the insulin 
sensitivity by increasing the transcription of insulin 
responsive genes. It enhances GLUT-4 and glucokinase 
activity, decreases inflammatory cytokines such as 
tumor necrosis factor alpha and resistin, inhibits 
gluconeogenesis and increases glucose uptake by the 
cells.  In our study the plasma glucose level reduced to 
67% by administration of 10 mg/kg pioglitazone 
intraperitoneally for 6 days. Similarly in an earlier 
study, the oral administration of 10 mg/kg body 
weight of pioglitazone for 7 days in HFD-fed/low 
dose STZ treated T2DM rat model (Sprague Dawley 
rats) presented with the reduction in plasma glucose 
level by 34.2%.21 The variation in level of effect 
between the two studies might be due to the difference 
in animal type and method of drug administration. 
Another study found that pioglitazone significantly 
improved glucose metabolism in HFD/STZ treated 
diabetic Wistar albino rats when 2.7 mg/kg/day 
pioglitazone was administered orally for 21 days 
which resulted in 32% reduction in blood glucose 
levels.22 These evidences indicate strong anti-
hyperglycemic action of pioglitazone. 
Levo carnitine in the dose of 200 mg/kg body 
weight of mice was administrated daily for 6 days to 
levo carnitine mice group and combined group. The 
same dose was used in a previous study for the same 
duration.20 Levo carnitine acts as a superoxide 
scavenger and a transporter of FFA that improves 
mitochondrial function by enhancing beta oxidation. It 
modulates the expression of glycolytic and 
gluconeogenic enzymes and thus regulates the hepatic 
glucose metabolism. In the present study, plasma 
glucose levels significantly reduced in levo carnitine 
group (330.50 + 33.54 mg/dl) when compared to 
diabetic control group (413.70 + 39.45 mg/dl). These 
results are consistent with the findings of another 
study in which administration of levo carnitine 
decreased blood glucose level in inbred strain of rats. 
Rahbar et al documented that fasting blood glucose 
levels in T2DM patients were significantly decreased 
by the oral intake of levo carnitine (1 gm/day) without 
any significant change in levels of HbA1c of these 
patients.24 In our study the most potent effect in 
lowering the plasma glucose level was observed in 
combined supplementation group (238.70 mg/dl). The 
combined administration of pioglitazone and levo 
carnitine  achieved normoglycemia in diabetic mice 
indicating that the above combination of drugs will be 
more beneficial if given for longer duration to control 
the hyperglycemia.  
    Insulin resistance is the hallmark of early 
pathological disorder in T2DM. Plasma glucose and 
TG/HDL ratio in the HFD fed mice were increased. 
The combination of fasting hyperglycaemia and 
increased TG/HDL ratio in HFD fed mice were 
indicative of glucose intolerance and insulin 
resistance.25 In this study, significant insulin resistance 
developed in diabetic control group (TG/HDL ratio = 
3.23). In another study, it was reported that the plasma 
triglyceride concentration, ratio of triglyceride to high 
density lipoprotein cholesterol concentration and 
insulin concentration were the most useful metabolic 
measures to identify the insulin resistant individuals.21 
     Pioglitazone administration caused significant 
reduction in insulin resistance of pioglitazone group 
by bringing the TG/HDL ratio below 1.8 which was 
1.48. This showed marked insulin sensitizing action of 
pioglitazone. Pioglitazone (PPARγ agonist) represents 
an important breakthrough in the therapy of insulin 
resistance. Its ability to increase adiponectin levels and 
insulin sensitivity suggests that there exists a link 
between adiponectin and insulin resistance. These 
findings are consistent with an earlier study that 
described the effect of pioglitazone which caused 
significant reduction in insulin resistance in 
individuals with T2DM by acting on the atherogenic 
lipoprotein profile.26  
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     Levo carnitine administration abolished the insulin 
resistance in carnitine group by bringing the TG/HDL 
ratio down to 1.824 and significant statistical 
difference was observed when compared to diabetic 
control group highlighting the insulin sensitizing 
action of levo carnitine. Levo carnitine causes increased 
transport of long chain fatty acids into the 
mitochondria for metabolism by its strong effect on the 
reaction catalysed by carnitine palmitoyl transferase-1 
(CPT-1). High levels of levo carnitine cause reduction 
in cytosolic long chain acyl-Co A levels which might 
have improved the insulin signalling in diabetic mice 
of carnitine group. Insulin resistance improved 
significantly when obese diabetic transgenic mouse 
model was administered with levo carnitine orally 
(0.50% in diet i.e. 1 gm/kg/day) for three weeks.27  
The significant improvement in IR (TG/HDL ratio = 
1.25) in combined supplemented group showed a 
positive contribution of pioglitazone in normalizing 
the plasma glucose levels and levo carnitine in 
shuttling the fatty acids into the mitochondria for 
oxidation, resulting in improved glycaemic control. 
     The serum adiponectin level was measured in all 
the four groups. Adiponectin is one of the most 
abundant secretory protein from adipose tissues in 
rodents and humans. A reduction in adiponectin level 
has been documented in obesity and T2DM in 
different studies and it has been suggested that 
adiponectin plays a protective role against insulin 
resistance. Weyer et al documented that the degree of 
hypo-adiponectinemia in people with obesity and 
T2DM is more closely related to the degree of insulin 
resistance and hyperinsulinemia. They also reported 
that adiponectin is the only adipose specific hormone 
which is exclusively produced in white adipose tissue 
and is negatively regulated in obesity.28 In our study 
the serum adiponectin level was found low in diabetic 
control mice (3.97 ng/dl). These findings are consistent 
with the results of another study on streptozotocin 
induced T2DM Sprague Dawley rats in which low 
adiponectin level was estimated in obese and diabetic 
groups (3.35 ng/dl in obese and 2.45 ng/dl in diabetic 
rats).29 
      Thiazolidinedione (TZDs) increases plasma 
adiponectin level in animal models of obesity and 
diabetes and patients with T2DM. The improvement in 
insulin sensitivity in response to TZDs administration 
is associated with an increase in circulating 
adiponectin. Pioglitazone supplementation (10 mg/kg 
body weight) was given for six days to pioglitazone 
group and was found to cause significant increase 
(p˂0.001) in serum adiponectin level (7.81 ng/dl) as 
compared to the diabetic control group (3.97 ng/dl). 
Similarly, it was demonstrated in an earlier 
experiment that insulin resistance and diabetes 
improved significantly in ob/ob mice in association 
with significant up-regulation of serum adiponectin 
levels with 14 days administration of 10 mg/kg body 
weight of pioglitazone. This strongly indicates that 
adiponectin is casually involved in the pioglitazone 
mediated amelioration of hepatic insulin resistance 
and diabetes.13 The finding of another investigation 
correspond to results of present study i.e. the 
administration of TZDs significantly increased the 
plasma adiponectin concentration in insulin resistant 
rodents (db/db mice).6 The effects of in vivo PPARγ 
agonist (TZDs) treatment on plasma adiponectin levels 
in db/db mice and HFD/STZ treated mice found that 
mice treated with rosiglitazone at a dose of 10 
mg/kg/day for 11 days (by daily oral gavage) showed 
three fold increase in mean plasma adiponectin level. 
Whereas, in our study, pioglitazone caused two fold 
increase in serum adiponectin level. The variance in 
degree of increase in adiponectin level may be due to 
the  duration, type and method of drug 
administration.30  
      Levo carnitine supplementation increased serum 
adiponectin level in levo carnitine group but difference 
was not significant when compared to the diabetic 
control group. An earlier study reported that chronic 
treatment with acetyl levo carnitine (oral 
supplementation) ameliorated the arterial 
hypertension, insulin resistance and 
hypoadiponectinemia in type-2 diabetic subjects at 
increased cardio vascular risk.16 A research conducted 
on obese women revealed that ingestion of levo 
carnitine 4 mg/kg body weight every other day for 8 
weeks along with physical exercise resulted in a 
decreased leptin level and increased adiponectin 
level.31 In our study the strongest effect on adiponectin 
level was seen in combined supplemented group. The 
serum adiponectin level increased significantly (8.35 
ng/dl) in this group as compared to the diabetic group 
(3.97 ng/dl).This study not only supported previous 
studies of individual efficacy of pioglitazone and levo 
carnitine but also suggested that increasing the 
number of mice and duration of the supplementation 
of both pioglitazone and levo carnitine may yield more 
promising prospects in this area.   
 
Conclusion 
Combined supplementation of pioglitazone and levo 
carnitine decreases plasma glucose, insulin resistance 
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and enhances the serum adiponectin levels that 
improves the insulin sensitivity in type 2 diabetic mice.  
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